The iboga experience — using whole-plant root bark from Tabernanthe iboga rather than isolated ibogaine — runs 12–24 hours across three distinct phases. People who have done ibogaine sessions elsewhere and think they know what to expect are sometimes caught off guard. Whole-plant ceremony is not the same as pharmaceutical ibogaine. It involves more alkaloids, a different progression, and a ceremonial context rooted in the Bwiti tradition of Central Africa that does not exist in a clinical dose.
In short: Whole-plant iboga ceremony uses root bark containing ibogaine alongside 30+ additional alkaloids. The active experience runs 12–24 hours across three phases. The ceremonial frame — preparation, presence of experienced practitioners, post-ceremony structure — is part of what makes it different from isolated ibogaine administered clinically. Integration is not a bonus service. It is what determines whether any lasting change results.
Iboga and Ibogaine Are Not the Same Thing
Ibogaine is one alkaloid — the primary psychoactive compound extracted from Tabernanthe iboga and concentrated into a measurable, dosed compound. Pharmaceutical ibogaine hydrochloride (HCl) is what most clinical research uses and what most certified providers outside of traditional settings administer.
Iboga root bark is the whole plant. It contains ibogaine at roughly 2–5% of dry weight, alongside ibogaline, ibogamine, tabernanthine, and more than 30 additional alkaloids. The pharmacological interaction between those compounds is not fully characterised. Practitioners who work with both preparations describe a different quality to the experience — less linear, less predictable, and not amenable to the same precise dosing calculations used for ibogaine HCl.
The distinction matters because the Bwiti tradition uses whole-plant root bark, not isolated ibogaine. What is passed down through that lineage — the ceremonial songs, the preparation protocols, the understanding of how the medicine moves through the body — was developed with the whole plant. Isolating the primary alkaloid and removing it from that context is a different practice. Neither is superior. They are suited to different situations and different people.
What the Whole-Plant Preparation Changes
Compared to isolated ibogaine HCl, whole-plant iboga ceremony differs in several ways that are relevant before you decide which preparation is appropriate for you.
Dosing. Ibogaine HCl is dosed by body weight — typically 15–20 mg/kg for a full therapeutic flood dose, preceded by a test dose of 2–3 mg/kg to assess cardiac response. Root bark contains variable alkaloid concentrations per gram. The attending practitioner must have direct experience with the specific preparation being used. This is one reason that lineage experience matters more in whole-plant work than credentials alone.
Onset and progression. Root bark tends to have a more gradual onset than high-dose ibogaine HCl. The three-stage progression — visionary, introspective, residual — is consistent with both preparations, but the transitions can be less abrupt with whole plant.
Duration. Traditional Bwiti initiatory ceremony can run 24–48 hours or longer. Therapeutic iboga ceremony with root bark in a contemporary setting typically runs 12–24 hours — comparable to ibogaine HCl, with individual variation.
Ceremonial context. The whole-plant preparation does not remove the medicine from its context. The Bwiti ceremonial frame — the specific songs, the darkness, the presence of practitioners who have sat with the medicine many times themselves — is part of the preparation and part of the processing. This changes what participants experience before the medicine is taken and what is available to them during it.
For people considering ibogaine alongside 5-MeO-DMT or evaluating which medicine addresses their situation, the preparation type is one of several relevant variables — not a shortcut to a decision.
The Three Stages of the Iboga Experience
The three stages are consistent across iboga and ibogaine, with variation in how abruptly they transition in whole-plant ceremony.
Stage one: visionary (hours 1–8). The acute phase. Ibogaine interacts with multiple receptor systems simultaneously — opioid receptors, NMDA glutamate receptors, the serotonin transporter, and sigma-2 receptors. The subjective experience tends toward autobiographical imagery, often presented with unusual clarity and without the emotional charge that normally makes personal material difficult to examine. About 60–70% of participants report significant visual content during this phase. For the remaining 30–40%, the experience is more somatic and emotional without strong imagery. The therapeutic process appears to occur in both cases.
What is consistent across both groups: the material that surfaces is personal and specific. It is not abstract or symbolic. It is not pleasant. The medicine does not show people what they hope to find. It shows them what is there.
Stage two: introspective (hours 8–24). Visual content diminishes. A period of unusual mental clarity follows — the ability to examine patterns in behaviour and history without the emotional reactivity that normally makes that examination painful. This is the phase most consistently described as therapeutically significant by practitioners who work with the medicine regularly. Physical fatigue is significant. Sleep is not possible.
Stage three: residual (hours 24–72).Ataxia, disrupted sleep, sensitivity to light and sound, and fatigue persist and gradually resolve without intervention. Noribogaine — ibogaine's active metabolite — enters circulation during the acute phase and remains pharmacologically active for weeks to months. This sustained activity is the neuroplasticity window: new patterns are more accessible, existing ones more malleable. What happens during this window determines the long-term outcome of the ceremony.
What Participants Consistently Report
There is no consistent account of what the iboga experience shows. The content varies entirely by person.
What is consistent is the direction. It is confrontational rather than expansive. It tends toward what the person has been avoiding, not what they hope to find. Participants who arrive expecting something spiritually gratifying are regularly surprised by how direct it is — not hostile, not punishing, but direct in a way that leaves no room for comfortable interpretations.
The 2023 Stanford study published in Nature Medicine found 88% reduction in PTSD symptoms, 87% in depression, and 81% in anxiety at one month in 30 special operations veterans with treatment-resistant conditions. That study used ibogaine HCl rather than whole-plant root bark — but the underlying mechanism is the same. Ibogaine, whether extracted or whole-plant, acts on the same receptor systems. The numbers are the best evidence available. They come from a population of 30, without a placebo arm — limitations worth naming alongside results compelling enough to stand with them included.
A 2018 survey of ibogaine outcomes published in Substance Abuse and Rehabilitation found 80% of participants reported significant withdrawal reduction at the time of treatment. Long-term abstinence without structured integration support was substantially lower. The medicine opens a window. What happens in that window is a separate question.
Iboga is not comparable to ayahuasca on any meaningful scale. Different mechanism, different duration, different tradition, different clinical evidence base. People who ask “which is more intense?” are usually asking the wrong question.
The Physical Demands
The iboga experience is physically demanding in ways that are worth understanding before you commit to a ceremony date.
Nausea is common, particularly in the first six hours. Ataxia — loss of coordination and balance — means participants cannot walk unsupported during the acute phase. Most spend the entire active ceremony lying down. Auditory phenomena, including ambient sounds seeming amplified and music appearing with unusual clarity and structure, are common throughout. Sensitivity to light is consistent across participants. These effects are not signs of something going wrong. They are the expected pharmacological profile of the medicine.
Sleep is not possible during the active experience. Most people cannot sleep for the first 24–36 hours after dosing. This is not insomnia in the conventional sense — noribogaine has stimulant properties that temporarily disrupt sleep architecture. It resolves without intervention, typically by the end of the first full day after ceremony.
This is not a ceremony for someone in poor baseline health. Medical screening identifies cardiac and pharmacological contraindications — it does not substitute for physical preparation. Someone who arrives sleep-deprived, actively withdrawing from a substance without proper preparation, or acutely malnourished will find the physical experience significantly harder. Preparation matters as much as screening.
The on-site physician and continuous cardiac monitoring are present because ibogaine prolongs the QT interval in all participants, even those without pre-existing cardiac conditions. This is not a formality. It is how the cardiac risk is managed. A provider who does not run continuous cardiac monitoring is not managing it — they are hoping nothing happens. See the guide to how ibogaine is administered for what the full medical protocol involves.
The Integration Period
The ceremony ends. The noribogaine does not.
Ibogaine's active metabolite enters circulation during the acute phase and remains pharmacologically present for weeks to months. Neuroplasticity is elevated during this window — new patterns are more accessible, existing ones more malleable. This is not a metaphor. It is a measurable neurological state sustained by a compound that continues to act on opioid and glutamate receptors long after the acute experience has ended.
What is done during this window determines whether the iboga experience produces lasting change. Integration support — structured coaching, environmental changes, deliberate practice — is not a bonus service that separates premium providers from budget ones. It determines whether the ceremony produces lasting change at all. The ceremony opens the window. Integration is the work done while it is open.
A participant who completes an iboga ceremony with full medical supervision, processes the material the medicine produced, and then returns immediately to the same environment and the same unaddressed conditions that produced the original problem will typically find themselves back where they started within six weeks. This is not a rare outcome. It is the default outcome when structured integration is absent.
The 2023 Stanford study found 88% reductions in PTSD symptoms and 87% in depression at one month — a period well after the medicine had cleared the body. Those outcomes occurred alongside post-ceremony support. They were not produced by the ceremony alone.
Integration coaching at Transcend costs $150–$300 CAD per session. Most participants engage in three or more sessions during the first four weeks following ceremony. The coaching is not required in the sense that you are obligated to purchase it. It is not optional in the sense that skipping it substantially increases the probability of returning to where you started.
Who Is Not a Candidate for Iboga Ceremony
This list is not short, and none of it is negotiable.
QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Ibogaine prolongs the QT interval in all participants — a cardiac mechanism that can trigger ventricular arrhythmia in people with underlying conditions. A 12-lead EKG identifies this before ceremony, not during it. Any provider who does not require a pre-ceremony EKG is not operating safely.
Current SSRIs or SNRIs without a completed supervised taper. Ibogaine acts on the serotonin transporter — the same mechanism as SSRIs. Combining active SSRI use with ibogaine creates real risk of serotonin syndrome. In severe cases, this is fatal. No case is an exception to this rule.
Methadone, without a specific transition protocol.Methadone's half-life and receptor affinity require a managed transition that cannot be rushed or approximated. This is a protocol question, not a timing preference.
Active psychosis or schizophrenia spectrum disorder. The iboga experience amplifies what is present. Entering it in a state of psychotic break does not produce clarity. It produces amplified psychosis.
Severe liver or kidney disease. Ibogaine is metabolised hepatically. Compromised liver function changes the pharmacokinetics in ways that cannot be safely managed in a ceremony context.
Lithium, most antipsychotics, and certain other psychiatric medications. Interactions are documented. Review of all medications is mandatory before any ceremony date is considered.
Pregnancy.
Someone in acute psychiatric crisis. This is not an absolute contraindication in the pharmacological sense — no blood test reveals it. It is a clinical judgement. Someone in acute crisis is not an appropriate candidate at this time, regardless of how much they want access to the medicine.
Someone who is primarily seeking a mystical experience, or who has decided that iboga is going to be easier than conventional treatment, has probably misunderstood what the medicine does. It is not the medicine for people who want to skip the work. It is, at best, a concentrated encounter with the work itself.
Is This Right for You?
Iboga ceremony at Transcend costs $2,000–$5,000 CAD. That range covers the on-site physician, continuous cardiac monitoring throughout the 12–24 hour active experience, the medicine, facilitation, and the 2–3 day supervised recovery period. Integration coaching is discussed separately during intake.
The application process begins with a conversation, not a payment. Medical screening is completed before any ceremony date is confirmed. No deposit is required until candidacy is established. See the guide to ibogaine treatment in Canada for what the full intake process involves.
If you have been working on something — a pattern, a history, a stuck place — and conventional approaches have not moved it, iboga ceremony may be the right next step. If you are in acute crisis and have decided this is the solution, it is not the right time. The experience amplifies what is present. That matters.
Applications are reviewed within 2–3 business days. Reach out to begin the process.
Frequently Asked Questions
Sources
Mithoefer et al. “Ibogaine treatment outcomes for veterans with PTSD and TBI.” Nature Medicine, 2023. · Brown TK, Alper K. “Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.” American Journal of Drug and Alcohol Abuse, 2018. · Schenberg EE. “Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development.” Frontiers in Psychiatry, 2017.